Kristian Wachtell

Summary

Affiliation: Copenhagen County University Hospital
Country: Denmark

Publications

  1. ncbi request reprint Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark
    Am Heart J 148:538-44. 2004
  2. ncbi request reprint Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark
    Am Heart J 144:1057-64. 2002
  3. ncbi request reprint Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Am Coll Cardiol 45:705-11. 2005
  4. doi request reprint Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study)
    Kristian Wachtell
    Copenhagen University Hospital in Glostrup, Glostrup, Denmark
    Am J Cardiol 106:999-1005. 2010
  5. doi request reprint In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study
    Kristian Wachtell
    Department of Cardiology, Rigshospitalet, Denmark
    Blood Press 19:169-75. 2010
  6. ncbi request reprint Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    Ann Intern Med 139:901-6. 2003
  7. ncbi request reprint Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation
    Kristian Wachtell
    Rigshospitalet, Department of Cardiology B2142, The Heart Center, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Curr Cardiol Rep 8:356-64. 2006
  8. doi request reprint In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study
    Kristian Wachtell
    Glostrup University Hospital, Glostrup, Denmark
    J Hypertens 28:1541-6. 2010
  9. ncbi request reprint The effect of angiotensin receptor blockers for preventing atrial fibrillation
    Kristian Wachtell
    Department of Cardiology B2142, Rigshospitalet, The Heart Center, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Curr Hypertens Rep 9:278-83. 2007
  10. doi request reprint The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy
    Kristian Wachtell
    Department of Cardiology B2142, The Heart Center, Rigshospitalet, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Ther Adv Cardiovasc Dis 2:507-13. 2008

Collaborators

Detail Information

Publications97

  1. ncbi request reprint Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark
    Am Heart J 148:538-44. 2004
    ..LV systolic midwall shortening (MWS) may be impaired in hypertensive patients with normal LV ejection fraction. However, it is unclear whether impaired LV filling is related to depressed systolic midwall mechanics...
  2. ncbi request reprint Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark
    Am Heart J 144:1057-64. 2002
    ..Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear...
  3. ncbi request reprint Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Am Coll Cardiol 45:705-11. 2005
    ..We assessed the impact of antihypertensive treatment in hypertensive patients with electrocardiographic (ECG) left ventricular (LV) hypertrophy and a history of atrial fibrillation (AF)...
  4. doi request reprint Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study)
    Kristian Wachtell
    Copenhagen University Hospital in Glostrup, Glostrup, Denmark
    Am J Cardiol 106:999-1005. 2010
    ..However, normal in-treatment LV filling was strongly associated with a reduced risk for hospitalization for heart failure...
  5. doi request reprint In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study
    Kristian Wachtell
    Department of Cardiology, Rigshospitalet, Denmark
    Blood Press 19:169-75. 2010
    ..The aim of the present study was to examine whether changes in-treatment LA diameter were related to changes in risk of new-onset AF...
  6. ncbi request reprint Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    Ann Intern Med 139:901-6. 2003
    ..The partition values for urine albumin-creatinine ratio (UACR) used to identify microalbuminuria have been based on studies that predicted risk in diabetic patients...
  7. ncbi request reprint Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation
    Kristian Wachtell
    Rigshospitalet, Department of Cardiology B2142, The Heart Center, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Curr Cardiol Rep 8:356-64. 2006
    ..Agents that work through the renin-angiotensin-receptor system, the angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, are showing promise in animal and human studies...
  8. doi request reprint In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study
    Kristian Wachtell
    Glostrup University Hospital, Glostrup, Denmark
    J Hypertens 28:1541-6. 2010
    ..However, it remains unknown whether improvement of left ventricular systolic function during treatment reduces cardiovascular morbidity and mortality in hypertensive patients with preserved left ventricular function...
  9. ncbi request reprint The effect of angiotensin receptor blockers for preventing atrial fibrillation
    Kristian Wachtell
    Department of Cardiology B2142, Rigshospitalet, The Heart Center, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Curr Hypertens Rep 9:278-83. 2007
    ....
  10. doi request reprint The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy
    Kristian Wachtell
    Department of Cardiology B2142, The Heart Center, Rigshospitalet, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Ther Adv Cardiovasc Dis 2:507-13. 2008
    ..Differential effects of antihypertensive treatment on the left atrium and left ventricle may help prevent AF and reduce risk of stroke associated with hypertensive heart disease...
  11. ncbi request reprint Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Am Coll Cardiol 45:712-9. 2005
    ..This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF)...
  12. ncbi request reprint Is it time to change the definition of normal urinary albumin excretion?
    Kristian Wachtell
    Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark
    Nat Clin Pract Nephrol 4:650-1. 2008
    ..e. lower levels of albuminuria should be considered pathologic if concomitant cardiovascular disease is not present)...
  13. ncbi request reprint Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
    Kristian Wachtell
    Copenhagen County University Hospital, Glostrup, Denmark
    Circulation 105:1071-6. 2002
    ..It is well established that hypertensive patients with left ventricular (LV) hypertrophy have impaired diastolic filling. However, the impact of antihypertensive treatment and LV mass reduction on LV diastolic filling remains unclear...
  14. ncbi request reprint Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study
    Kristian Wachtell
    Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark
    Circulation 116:700-5. 2007
    ..Sudden cardiac death (SCD) occurs more often in patients with ECG left ventricular (LV) hypertrophy. However, whether LV hypertrophy regression is associated with a reduced risk of SCD remains unclear...
  15. ncbi request reprint Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study
    Kristian Wachtell
    Copenhagen County University Hospital, Glostrup, Denmark
    Circulation 106:227-32. 2002
    ..We have shown that hypertensive patients with left ventricular (LV) hypertrophy have decreased LV midwall mechanics, but the effect of antihypertensive therapy remains unclear...
  16. ncbi request reprint Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction
    Kristian Wachtell
    Laboratory of Cardiology, Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark
    Am Heart J 143:319-26. 2002
    ..However, the relationship between these markers of cardiovascular damage has not been evaluated in a large hypertensive population...
  17. ncbi request reprint Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study
    Kristian Wachtell
    Copenhagen County University Hospital, Glostrup, Denmark
    J Hypertens 20:405-12. 2002
    ....
  18. ncbi request reprint Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy
    Michael H Olsen
    Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark
    Am J Hypertens 18:1430-6. 2005
    ..We aimed to investigate whether they predicted cardiovascular (CV) events independently in patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy...
  19. ncbi request reprint Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex
    Michael H Olsen
    Research Center for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark
    J Hypertens 26:26-34. 2008
    ....
  20. ncbi request reprint Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study
    Hans Ibsen
    Glostrup University Hospital, Denmark
    Hypertension 45:198-202. 2005
    ..If albuminuria is not decreased by the patient's current antihypertensive and other treatment, further intervention directed toward blood pressure control and other modifiable risks should be considered...
  21. ncbi request reprint N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy
    Michael H Olsen
    Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Hypertens 24:1531-9. 2006
    ....
  22. ncbi request reprint Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide--three new cardiovascular risk markers--do they improve risk prediction and influence treatment?
    Michael H Olsen
    Research Center for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark
    Curr Vasc Pharmacol 8:134-9. 2010
    ....
  23. ncbi request reprint Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study
    Michael H Olsen
    Glostrup University Hospital, Denmark
    J Hypertens 24:775-81. 2006
    ..We wanted to investigate whether these prognostic improvements were independent...
  24. ncbi request reprint Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy
    Hans Ibsen
    Glostrup University Hospital, Denmark
    J Hypertens 22:1805-11. 2004
    ....
  25. ncbi request reprint N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population
    Michael H Olsen
    Research Center for Prevention and Health, Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Eur Heart J 28:1374-81. 2007
    ..The aim of this study was to determine whether they predicted CV events independently of established CV risk factors and whether they did so in an additive fashion...
  26. doi request reprint Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
    Michael Hecht Olsen
    Glostrup University Hospital, Glostrup, Denmark
    J Hypertens 27:567-74. 2009
    ..Beta-blockers and angiotensin II receptor blockers have different effects on lipids...
  27. ncbi request reprint Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy
    Michael H Olsen
    Glostrup University Hospital, Glostrup, Denmark
    J Hypertens 23:1083-90. 2005
    ..Therefore, we investigated the influence of blood pressure (BP) reduction with losartan versus atenolol on N-terminal pro-atrial natriuretic peptide (Nt-proANP) and N-terminal pro-brain natriuretic peptide (Nt-proBNP)...
  28. doi request reprint Risk prediction is improved by adding markers of subclinical organ damage to SCORE
    Thomas Sehestedt
    Department of Internal Medicine, The Cardiovascular Research Unit, Glostrup University Hospital, Nordre Ringvej, Glostrup, Denmark
    Eur Heart J 31:883-91. 2010
    ..It is unclear whether subclinical vascular damage adds significantly to Systemic Coronary Risk Evaluation (SCORE) risk stratification in healthy subjects...
  29. doi request reprint Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population
    Thomas Sehestedt
    Cardiovascular Research Unit, Department of Internal Medicine, Glostrup University Hospital, Denmark
    J Hypertens 27:2351-7. 2009
    ..However, ESH risk chart recommends measuring subclinical organ damage, whereas SCORE is based on traditional risk factors. We wanted to compare the predictive performance of the two charts...
  30. doi request reprint Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study
    Michael Hecht Olsen
    Department of Internal Medicine, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark
    Am Heart J 157:177-84. 2009
    ..The prognostic importance of hemoglobin is controversial. We investigated the prognostic importance of baseline and in-treatment hemoglobin in the LIFE study...
  31. doi request reprint Impact of QRS duration and morphology on the risk of sudden cardiac death in asymptomatic patients with aortic stenosis: the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
    Anders M Greve
    Department of Medicine B, The Heart Center, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark
    J Am Coll Cardiol 59:1142-9. 2012
    ..The aim of the study was to examine the predictive value of QRS duration and morphology during watchful waiting in asymptomatic patients with aortic stenosis (AS)...
  32. doi request reprint Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study
    Anders M Greve
    Department of Medicine B, The Heart Center, Rigshospitalet, Copenhagen, Denmark
    Am J Hypertens 25:1017-23. 2012
    ..Pharmaceutical differences in central hemodynamics might influence cardiac response to antihypertensive treatment despite similar lowering of brachial blood pressure (BP)...
  33. doi request reprint Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Anne Christine H Ruwald
    Department of Internal Medicine, Glostrup Hospital, Glostrup, Denmark
    J Hypertens 30:1252-9. 2012
    ..However, patient age often influences the choice of antihypertensive drugs. Therefore, we investigated the influence of age on the effects of losartan versus atenolol-based antihypertensive treatment...
  34. doi request reprint Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
    Casper N Bang
    Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark
    Am Heart J 163:690-6. 2012
    ..This effect has not been investigated on new-onset AF in asymptomatic patients with aortic stenosis (AS)...
  35. doi request reprint Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy
    Michael H Olsen
    Department of Internal Medicine, Glostrup Hospital, University of Copenhagen, DK 2600 Glostrup, Denmark
    J Hypertens 29:997-1004. 2011
    ....
  36. ncbi request reprint Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy)
    Michael H Olsen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Am J Cardiol 95:132-6. 2005
    ..AV sclerosis was associated with several CV risk factors and predicted CV events independently of prevalent CV disease and traditional CV risk factors, including LV mass and ejection fraction...
  37. ncbi request reprint Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts
    Thomas Sehestedt
    CV Research Unit, Department of Internal Medicine, Glostrup University Hospital, Denmark
    J Hypertens 30:1928-36. 2012
    ..We wanted to establish thresholds for three markers of TOD based on absolute CV risk in different risk chart categories...
  38. doi request reprint Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?
    Thomas Sehestedt
    Cardiovascular Research Unit, Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Hypertens 27:1165-71. 2009
    ..Medical treatment of healthy individuals with high normal blood pressure (BP) is recommended if there is subclinical organ damage (SOD). We examined which markers of SOD to use based on their supplementary prognostic value...
  39. ncbi request reprint N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome
    Michael H Olsen
    Research Center for Prevention and Health, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Hypertension 46:660-6. 2005
    ..The metabolic syndrome was associated with lower Nt-proBNP levels and shifted the positive relationship between Nt-proBNP and pulse pressure to the right, creating a possible link between the metabolic syndrome and hypertension...
  40. ncbi request reprint Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension
    Michael Hecht Olsen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark
    Am Heart J 144:530-7. 2002
    ..However, the relative influence of elevated blood pressure (BP) and various neurohormonal factors on cardiovascular remodeling in hypertension is unclear...
  41. ncbi request reprint Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy
    Michael H Olsen
    Departemtn fo Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, Copenhagen, Denmark
    Blood Press 14:177-83. 2005
    ..We wanted to investigate whether treatment with losartan, an angiotensin II receptor blocker, induced regression of carotid artery hypertrophy as compared to the beta-receptor blocker, atenolol...
  42. doi request reprint Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?
    Thomas Sehestedt
    Cardiovascular Research Unit, Department of Internal Medicine, Copenhagen University Hospital Glostrup, Denmark
    J Hypertens 30:513-21. 2012
    ..We wanted to investigate whether this additive effect of SOD was due to inaccurate blood pressure (BP) measurement or whether ambulatory BP (AMBP) added further to risk prediction...
  43. doi request reprint Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study
    Anders M Greve
    Rigshospitalet, Department of Medicine B2142, The Heart Center, 9 Blegdamsvej, DK 2100, Copenhagen, Denmark
    Circulation 125:346-53. 2012
    ..The prognostic impact of ECG left ventricular strain and left ventricular hypertrophy (LVH) in asymptomatic aortic stenosis is not well described...
  44. ncbi request reprint N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study
    Michael H Olsen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Hypertens 22:1597-604. 2004
    ....
  45. ncbi request reprint Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy)
    Michael H Olsen
    Glostrup University Hospital, Glostrup, Denmark
    Am J Cardiol 94:1076-80. 2004
    ....
  46. ncbi request reprint QT dynamics in risk stratification after myocardial infarction
    Berit T Jensen
    Laboratory of Experimental Cardiology, Department of Medical Physiology, University of Copenhagen, Copenhagen, Denmark
    Heart Rhythm 2:357-64. 2005
    ..A novel QT dynamics parameter, the QT/RR variability ratio (VR), was introduced in this study...
  47. ncbi request reprint Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy
    Andreas Kjaer
    Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet University Hospital, Copenhagen, Denmark
    Am J Cardiol 96:1692-8. 2005
    ..Endothelial dysfunction may contribute to the reduced perfusion reserve seen in hypertensive LVH...
  48. ncbi request reprint Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy
    Michael H Olsen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, Copenhagen, Denmark
    J Hypertens 23:891-8. 2005
    ..We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction...
  49. doi request reprint Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study
    Casper N Bang
    Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen Denmark Electronic address
    Int J Cardiol 168:2322-7. 2013
    ..It remains unclear whether these variations in LA parameters can predict new-onset atrial fibrillation (AF) in asymptomatic patients with aortic stenosis (AS)...
  50. doi request reprint Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study
    Anders M Greve
    Department of Medicine B, The Heart Center, Rigshospitalet, Copenhagen, Denmark
    Int J Cardiol 166:72-6. 2013
    ..The frequency and prognostic importance of atrial fibrillation (AF) in asymptomatic mild-to-moderate aortic stenosis (AS) has not been well described...
  51. doi request reprint Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study
    Casper N Bang
    aDepartment of Medicine, Weill Cornell Medical College, New York, USA bDepartment of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark cDepartment of Clinical Science, University of Bergen dDepartment of Heart Disease, Haukeland University Hospital, Bergen, Norway eDivision of Cardiology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA fInstitution of Public Health and Clinical Medicine, Umea University, Medicine Skellefteå, Umeå gDepartment of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden hDepartment of Medicine, Glostrup Hospital, Glostrup, Denmark
    J Hypertens 31:2060-8. 2013
    ..We evaluated left ventricular systolic function in a new four-group LVH classification based on left ventricular dilatation [high left ventricular end-diastolic volume (EDV) index and concentricity (LVM/EDV)] in hypertensive patients...
  52. doi request reprint New-Onset Atrial Fibrillation is Associated With Cardiovascular Events Leading to Death in a First Time Myocardial Infarction Population of 89 703 Patients With Long-Term Follow-Up: A Nationwide Study
    Casper N Bang
    Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark
    J Am Heart Assoc 3:e000382. 2014
    ..However, previous studies have reported conflicting results and no data exist to explain the underlying cause of higher death rates in these patients...
  53. doi request reprint Left atrial volume as predictor of valve replacement and cardiovascular events in patients with asymptomatic mild to moderate aortic stenosis
    Morten Dalsgaard
    Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Echocardiography 30:1008-14. 2013
    ..We hypothesized that LA volume was predictive of aortic valve replacement (AVR) and cardiovascular events in a large cohort of patients with asymptomatic mild to moderate aortic valve stenosis...
  54. doi request reprint Differences in cardiovascular risk profile between electrocardiographic hypertrophy versus strain in asymptomatic patients with aortic stenosis (from SEAS data)
    Anders M Greve
    Department of Medicine B, The Heart Center, Rigshospitalet, Copenhagen, Denmark
    Am J Cardiol 108:541-7. 2011
    ..Moreover, clinical covariates differ significantly between patients with electrocardiographic strain and those with LV hypertrophy by Sokolow-Lyon voltage criteria and Cornell voltage-duration criteria...
  55. ncbi request reprint Pre-discharge exercise test for evaluation of patients with complete or incomplete revascularization following primary percutaneous coronary intervention: a DANAMI-2 sub-study
    Nana Valeur
    Department of Cardiology, The Heart Center, Copenhagen University Hospital, Copenhagen, Denmark
    Cardiology 109:163-71. 2008
    ..It is unclear whether the completeness of revascularization impacts on the prognostic value of an exercise test after primary percutaneous coronary intervention (PCI)...
  56. ncbi request reprint Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension
    Michael H Olsen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, Copenhagen, Denmark
    Am J Hypertens 15:398-404. 2002
    ..However, it is unclear whether this impairment is explained solely by endothelial dysfunction, or whether it is associated with structural vascular changes and reduced vasodilatory capacity...
  57. ncbi request reprint Heart rate versus heart rate variability in risk prediction after myocardial infarction
    Steen Z Abildstrom
    Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark
    J Cardiovasc Electrophysiol 14:168-73. 2003
    ....
  58. doi request reprint Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest
    Helle Søholm
    Department of Cardiology 2142, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Resuscitation 84:162-7. 2013
    ..The aim of this study is to compare 30-day and long-term mortality after OHCA at tertiary heart centres and non-tertiary university hospitals...
  59. doi request reprint The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: a systematic review and meta-analysis
    Casper N Bang
    Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark
    Int J Cardiol 167:624-30. 2013
    ..However, the current evidence on the benefit of statins unrelated to invasive cardiac interventions has not been clarified systematically...
  60. doi request reprint Left atrial volume in patients with asymptomatic aortic valve stenosis (the Simvastatin and Ezetimibe in Aortic Stenosis study)
    Morten Dalsgaard
    Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Am J Cardiol 101:1030-4. 2008
    ..Furthermore, LA volume is related to AVA even when adjusting for other known risk factors for increased LA volume including of measurements of diastolic function...
  61. doi request reprint Does lowering cholesterol have an impact on the progression of aortic stenosis?
    Anders M Greve
    Department of Medicine B, Rigshospitalet, The Heart Center, Copenhagen, Denmark
    Ther Adv Cardiovasc Dis 2:277-86. 2008
    ..Finally, we review if computerized tomography, biomarkers, and clinical characteristics such as left ventricular ejection fraction, can be useful in stratifying patients to potential benefit of statin therapy...
  62. ncbi request reprint Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study)
    Jonathan N Bella
    Cornell Medical Center, New York, New York, USA
    Am J Cardiol 89:337-41. 2002
  63. doi request reprint Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Marcello Chinali
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Hypertens 26:1472-6. 2008
    ....
  64. doi request reprint Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study
    Zhibin Li
    Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA
    J Hypertens 26:1244-9. 2008
    ..Whether left bundle branch block is associated with cardiovascular events in hypertension with electrocardiographic left ventricular hypertrophy is unknown...
  65. doi request reprint Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study
    Vittorio Palmieri
    Division of Cardiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Am J Hypertens 21:701-7. 2008
    ..In cross-sectional data in hypertensive subjects, brachial pulse pressure (PP)/Doppler stroke index (SVi), (PP/SVi) correlates weakly but significantly with left ventricular (LV) mass and relative wall thickness (RWT)...
  66. doi request reprint Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Silvana Cicala
    Division of Cardiology, Weill Cornell Medical College, New York, New York 10021, USA
    J Hypertens 26:806-12. 2008
    ..We examined whether 'in-treatment' wall motion abnormalities predicted outcome in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension echocardiographic substudy...
  67. ncbi request reprint Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study
    Hans Ibsen
    Medical Department M, Glostrup Hospital, DK 2600 Glostrup, Denmark
    Diabetes Care 29:595-600. 2006
    ....
  68. ncbi request reprint Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study
    Giovanni de Simone
    Department of Clinical and Experimental Medicine, Federico II University Hospital, Via S Pansini, No 5, 80131 Naples, Italy
    Circulation 111:1924-31. 2005
    ....
  69. ncbi request reprint Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study)
    Kurt Boman
    Department of Medicine, Skellefteå County Hospital and Umeå University, 93186 Skellefteå, Sweden
    Am J Cardiol 95:280-3. 2005
    ..Patients with left ventricular hypertrophy had higher heart rates, left ventricular mass, and left atrial size independent of gender, blood pressure, or body mass index than physically active patients...
  70. ncbi request reprint Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study
    Jorge R Kizer
    Weill Medical College of Cornell University, New York, NY, USA
    Hypertension 45:46-52. 2005
    ....
  71. ncbi request reprint Prognostic significance of left ventricular mass change during treatment of hypertension
    Richard B Devereux
    Department of Medicine, New York Presbyterian Hospital, Cornell Medical Center, New York, NY 10021, USA
    JAMA 292:2350-6. 2004
    ..Increased baseline left ventricular (LV) mass predicts cardiovascular (CV) complications of hypertension, but the relation between lower LV mass and outcome during treatment for hypertension is uncertain...
  72. ncbi request reprint Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
    Richard B Devereux
    Cornell Medical Center, 525 E 68th St, New York, NY 10021, USA
    Circulation 110:1456-62. 2004
    ..An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol...
  73. ncbi request reprint Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
    Lars H Lindholm
    Department of Public Health and Clinical Medicine, Umea University Hospital, SE 901 85, Umea, Sweden
    Lancet 362:619-20. 2003
    ..Our results suggest losartan affords better protection against cardiac death from arrhythmias for patients with diabetes mellitus than does atenolol. Importantly, our analyses were exploratory and require confirmation...
  74. ncbi request reprint Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study
    Lasse Oikarinen
    Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
    Am Heart J 145:919-25. 2003
    ..Experimentally, regression of LVH normalizes ventricular electrophysiology...
  75. ncbi request reprint Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study
    Vittorio Palmieri
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Hypertens 21:781-7. 2003
    ..To evaluate the relationship between arterial stiffness estimated by the pulse pressure/stroke index ratio (PP/SVi) and prognostically relevant abnormalities of left ventricular geometry and function...
  76. ncbi request reprint Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment
    Gerard P Aurigemma
    Department of Medicine, Division of Cardiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Am J Hypertens 16:180-6. 2003
    ..Accordingly, our aim was to study the relationship between prior treatment and both baseline and 1-year echocardiographic LV mass in subjects enrolled in the Losartan Intervention For Endpoint reduction (LIFE) study...
  77. ncbi request reprint Left ventricular hypertrophy is associated with reduced vasodilatory capacity in the brachial artery in patients with longstanding hypertension. A LIFE substudy
    Michael Hecht Olsen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup Hospital, University of Copenhagen, Denmark
    Blood Press 11:285-92. 2002
    ..Whether similar relations exist in patients with longstanding hypertension and target organ damage remain to be elucidated...
  78. ncbi request reprint Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
    Lars H Lindholm
    Steno Diabetes Centre, Gentofte, Denmark
    J Hypertens 20:1879-86. 2002
    ..There has been uncertainty about the risk of new-onset diabetes in hypertensive individuals treated with different blood pressure-decreasing drugs...
  79. ncbi request reprint Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study
    Richard B Devereux
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Hypertens 20:1445-50. 2002
    ..To examine the time course of left ventricular (LV) geometric response to blood pressure (BP) control during 2 years of systematic antihypertensive treatment...
  80. ncbi request reprint Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
    Eva Gerdts
    Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
    Hypertension 39:739-43. 2002
    ....
  81. ncbi request reprint Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy
    Eigil Fossum
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Clin Hypertens (Greenwich) 8:169-73. 2006
    ..The difference in carotid plaque index increase between the treatment groups during 3 years of treatment could not be statistically linked to specific treatments in the present substudy...
  82. ncbi request reprint High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors
    Michael H Olsen
    Research Center for Prevention and Health, Glostrup University, Denmark
    J Hypertens 24:655-61. 2006
    ....
  83. doi request reprint Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS Substudy)
    Dana Cramariuc
    Institute of Medicine, University of Bergen, Bergen, Norway
    Am J Cardiol 101:510-5. 2008
    ..Women have higher stress-corrected indexes of systolic function independent of LV geometry or size, wall stress, older age, or more concomitant hypertension...
  84. doi request reprint Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study
    Eva Gerdts
    Institute of Medicine, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Hypertension 51:1109-14. 2008
    ..07; P<0.01). Hypertensive women in this study retained higher left ventricular ejection fraction and stress-corrected midwall shortening in spite of less hypertrophy regression during long-term antihypertensive treatment...
  85. doi request reprint Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study
    Peter M Okin
    Greenberg Division of Cardiology, Weill Medical College of Cornell University, New York, New York, USA
    Am J Hypertens 21:273-9. 2008
    ..Although albuminuria and the electrocardiographic (ECG) strain pattern each predict development of heart failure (HF), whether combining albuminuria and strain improves prediction of new HF is unclear...
  86. ncbi request reprint Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy
    Stanley S Franklin
    Heart Disease Prevention Program, University of California, Irvine, CA 92697, USA
    Hypertension 46:492-9. 2005
    ..In conclusion, losartan compared with atenolol reduces the risk of stroke, new-onset diabetes, and new-onset atrial fibrillation in the LRG and the HRG...
  87. ncbi request reprint Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy
    Lia E Bang
    Naestved Hospital, Naestved, Denmark
    Blood Press 16:392-7. 2007
    ..Our aim was to investigate the effect of losartan- and atenolol-based treatment on 24-h ambulatory BP and heart rate (HR) in LIFE...
  88. ncbi request reprint Prevalence and prognostic implications of ST-segment deviations from ambulatory Holter monitoring after ST-segment elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention (a Danish Trial in Acute Myoc
    Lars Idorn
    Department of Medical Research, Funen Hospital, Svendborg, and Department of Cardiology, Copenhagen University Hospital, Denmark
    Am J Cardiol 100:937-43. 2007
    ..However, although STe is an independent predictor of mortality and nonfatal major cardiovascular events in patients treated with fibrinolysis, it does not predict outcome after PCI, perhaps because of more complete revascularization...
  89. ncbi request reprint Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study
    Vittorio Palmieri
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Hypertens 25:1079-85. 2007
    ....
  90. ncbi request reprint Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study
    Anne B Rossebø
    Division of Cardiology, Aker University Hospital, Oslo, Norway
    Am J Cardiol 99:970-3. 2007
    ..4+/-0.7 mmol/L (126 mg/dl). The SEAS Study is the largest randomized trial to date in patients with AS and will allow determination of the prognostic value of aggressive lipid lowering in such patients...
  91. ncbi request reprint Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Hypertens 25:871-6. 2007
    ....
  92. ncbi request reprint Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial
    Eva Gerdts
    Institute of Medicine, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Hypertension 49:311-6. 2007
    ....
  93. ncbi request reprint Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy
    Marina K Christensen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup Hospital, University of Copenhagen, Denmark
    Blood Press 15:198-206. 2006
    ..The aim of this study was to investigate the effects of losartan- vs atenolol-based antihypertensive treatment on circulating collagen markers beyond the initial blood pressure (BP) reduction...
  94. ncbi request reprint Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension
    Peter M Okin
    Greenberg Division of Cardiology, Weill Medical College of Cornell University, New York, NY 10021, USA
    JAMA 296:1242-8. 2006
    ..Although the presence and severity of electrocardiographic left ventricular hypertrophy (LVH) appear to predict development of AF, whether regression of electrocardiographic LVH is associated with a decreased incidence of AF is unclear...
  95. ncbi request reprint Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Vittorio Palmieri
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Hypertens 24:2079-84. 2006
    ....
  96. ncbi request reprint Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study
    Puneet Narayan
    Veterans Administration Medical Center, Washington, DC 20422, USA
    Hypertension 47:868-73. 2006
    ..Thus, in hypertensive LVH, higher oxygen delivery capacity is associated with higher LV mass and impaired early diastolic LV filling...
  97. ncbi request reprint Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)
    Eva Gerdts
    Haukeland University Hospital, Bergen, Norway
    Am J Cardiol 89:399-402. 2002
    ....